<DOC>
	<DOCNO>NCT00402467</DOCNO>
	<brief_summary>The study drug , BAY59-7939 , new drug currently test prevention VTE . It directly inhibit factor Xa , blood component pathway lead coagulation ( clot blood cell ) . It available tablet . The purpose study compare safety efficacy BAY59-7939 safety efficacy license drug Enoxaparin . Enoxaparin , so-called low molecular heparin , approve widely use area thromboprophylaxis give daily subcutaneously . In study 4 different dos investigational drug BAY59-7939 test comparison Enoxaparin . You receive study either one follow BAY59-7939 treatment Enoxaparin . The following dos BAY59-7939 test : Dose I ; Dose II , Dose III , Dose IV . This study run approximately 7 month number country . In total , 600 patient may participate study .</brief_summary>
	<brief_title>An Oral , Direct Factor Xa Inhibitor , BAY59-7939 , Prophylaxis Against Venous Thromboembolism After Total Knee Replacement : Dose-Ranging Study</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Male subject age 18 year postmenopausal female subject Subjects schedule elective total knee replacement Subjects write informed consent participation receive detailed write oral information previous study specific procedure Related medical history : Any prior DVT PE Myocardial infarction ( MI ) , TIA ischaemic stroke within last 6 month prior randomization History heparininduced thrombocytopenia , allergy heparin Intracerebral intraocular bleeding within last 6 month prior randomization History gastrointestinal disease ( e.g . active peptic ulcer ) gastrointestinal bleeding within last 6 month prior randomization History presence gastrointestinal disease could result impaired absorption study drug ( e.g . severe active inflammatory bowel disease , short gut syndrome ) Amputation one leg Related current symptom finding : Heart insufficiency NYHA IIIIV Congenital acquire haemorrhagic diathesis ( PT INR/aPTT within normal limit ) include patient acquire congenital thrombophilia Thrombocytopenia ( platelet &lt; 100,000/Âµl ) Macroscopic haematuria Allergy contrast medium Severe hypertension ( SBP &gt; 200mmHg , DBP &gt; 100 mmHg ) Impaired liver function ( transaminases &gt; 2 x ULN ) Impaired renal function ( serum creatinine &gt; 1.5 x ULN decrease creatinine clearance &lt; 30ml/min ) Active malignant disease Presence active peptic ulcer gastrointestinal disease increase risk gastrointestinal bleeding Body weight &lt; 45 kg Drug alcohol abuse Related current treatment : Therapy oral anticoagulant ( e.g . phenprocoumon , warfarinsodium , heparins factor Xa inhibitor study medication ) fibrinolytic therapy Therapy acetylic salicylic acid thrombocyte aggregation inhibitor ( e.g . clopidogrel , dipyridamole ticlopidine ) stop one week enrollment . Patient able stop ASA therapy exclude All drug influence coagulation , ( exception : NSAIDs half life &lt; 17 hr allow ) Systemic topical treatment azole compound ( e.g . ketoconazole , fluconazole , itraconazole ) . Azole compound stop least four day enrollment Miscellaneous : Planned intermittent pneumatic compression active treatment period Planned epidural anaesthesia indwell epidural catheter ( spinal epidural anaesthesia without indwell catheter allow ) Therapy another investigational product within 30 day prior start study Concomitant participation another trial study Removal Subjects Study : A subject withdraw one discontinue clinical study reason . Subjects may withdraw study follow reason : At request request legally acceptable representative If , investigator 's opinion , continuation study would detrimental subject 's wellbeing At specific request sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Prevention venous thromboembolism</keyword>
</DOC>